The global type 2 diabetes market size is expected to reach around US$ 61.6 billion by 2030 from US$ 29.81 billion in 2021 and is expected to grow at an impressive double-digit rate of 8.4% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global type 2 diabetes market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1663
Report Scope of the Type 2 Diabetes Market
| Report Coverage | Details |
| Market Size by 2030 | USD 61.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.4% |
| North America Market Share in 2021 | 35% |
| Fastest growing Region | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Report Highlights
- On the basis of drug class, insulin segment holds the largest market share in the global type 2 diabetes market. Insulin is a widely prescribed medication for the treatment of type 2 diabetes. Insulin improves the body’s metabolism while also attempting to stimulate the immune system. Insulin also aids in the regulation of blood sugar levels in the body.
- On the basis of application, retail pharmacies segment holds the largest market share in the global type 2 diabetes market. Retail pharmacies have a vast selection of pharmaceuticals and medications. Drugs sold in retail pharmacies are inexpensive and accessible to the general public.
Market Dynamics
Drivers
Surge in demand for insulin
The type 2 diabetes market growth prospects exist in the insulin segment of the market. The type 2 diabetes affects a large number of people. It’s one of the main reasons why insulin medicines are in such high demand. The insulin segment offers tremendous development and growth opportunities due to product variety and innovation. Thus, surge in demand for insulin are driving the growth of global type 2 diabetes market over the projected period.
Restraints
Lack of healthcare infrastructure in various nations
In some diabetic instances, the healthcare infrastructure is inadequate. It is a major hurdle for the type 2 diabetes market. Drug development, research, and other general market conditions are all hampered by weak healthcare infrastructure. In some regions, a lack of health infrastructure can make type 2 diabetes market expansion impossible. Furthermore, in certain areas, there may be less demand. As a result, lack of healthcare infrastructure in various nations is restricting the type 2 diabetes market growth.
Opportunities
Growing investments in research and development
The introduction of generic insulin and the rapidly expanding demand for innovative insulin in the regulation of blood sugar levels in type 2 diabetes are expected to drive the growth of global type 2 diabetes market. Lispro, a generalform of rapid acting Humalog insulin was launched in March 2019 by Eli Lilly and Company. It will be available in the U.S. for low price as compared to Humalog, making it more affordable for type 2 diabetes patients. Thus, growing investments in research and development is providing growth prospects for the global type 2 diabetes market.
Challenges
Stringent government regulations
The market challenges are imposed by rigorous government regulations. Diabetes medications are available in a broad variety around the world. Regulatory requirements also cause delays in the approval of new medications. The medicine approval regulator’s standards are stringent, influencing the type 2 diabetes market’s supply and output. As a result, stringent government regulations are major challenges for the growth of global type 2 diabetes market over the projected period.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global type 2 diabetes market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global type 2 diabetes market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global type 2 diabetes market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for type 2 diabetes are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global type 2 diabetes market include:
- Amgen Inc.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Co. Ltd
- Eli Lilly and Co.
- Merck & Co. Inc
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd
Market Segmentation:
By Drug Class
- Dipeptidyl Peptidase-4
- Inhibitors
- Glucagon-Like Peptide
- Receptor Agonists
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Sulfonylureas
- Secretagogues
- Biguanides
- Sodium Glucose Cotransport 2 Inhibitors
By Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Regional Analysis:
The geographical analysis of the global type 2 diabetes market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global type 2 diabetes Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global type 2 diabetes market in 2030?
- What is the expected CAGR for the type 2 diabetes market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global type 2 diabetes market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Type 2 Diabetes Market
5.1. COVID-19 Landscape: Type 2 Diabetes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Type 2 Diabetes Market, By Drug Class
8.1. Type 2 Diabetes Market, by Drug Class Type, 2022-2030
8.1.1. Dipeptidyl Peptidase-4
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Inhibitors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Glucagon-Like Peptide
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Receptor Agonists
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Thiazolidinediones
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Alpha-Glucosidase Inhibitors
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Sulfonylureas
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Secretagogues
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Biguanides
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Sodium Glucose Cotransport 2 Inhibitors
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Type 2 Diabetes Market, By Application
9.1. Type 2 Diabetes Market, by Application, 2022-2030
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Type 2 Diabetes Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
Chapter 11. Company Profiles
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca PLC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Boehringer Ingelheim International GmbH
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Daiichi Sankyo Co. Ltd
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Eli Lilly and Co.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Merck & Co. Inc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novo Nordisk AS
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi SA
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Takeda Pharmaceutical Co. Ltd
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1663
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments